Metapneumovirus Infections and Respiratory Complications

Susanna Esposito, Maria Vincenza Mastrolia

Research output: Contribution to journalArticle

Abstract

Acute respiratory tract infections (ARTIs) are the most common illnesses experienced by people of all ages worldwide. In 2001, a new respiratory pathogen called human metapneumovirus (hMPV) was identified in respiratory secretions. hMPV is an RNA virus of the Paramyxoviridae family, and it has been isolated on every continent and from individuals of all ages. hMPV causes 7 to 19% of all cases of ARTIs in both hospitalized and outpatient children, and the rate of detection in adults is approximately 3%. Symptoms of hMPV infection range from a mild cold to a severe disease requiring a ventilator and cardiovascular support. The main risk factors for severe disease upon hMPV infection are the presence of a high viral load, coinfection with other agents (especially human respiratory syncytial virus), being between 0 and 5 months old or older than 65 years, and immunodeficiency. Currently, available treatments for hMPV infections are only supportive, and antiviral drugs are employed in cases of severe disease as a last resort. Ribavirin and immunoglobulins have been used in some patients, but the real efficacy of these treatments is unclear. At present, the direction of research on therapy for hMPV infection is toward the development of new approaches, and a variety of vaccination strategies are being explored and tested in animal models. However, further studies are required to define the best treatment and prevention strategies.

Original languageEnglish
Pages (from-to)512-521
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume37
Issue number4
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Metapneumovirus
Respiratory Tract Infections
Infection
Paramyxoviridae
Human respiratory syncytial virus
Hospitalized Child
Ribavirin
RNA Viruses
Mechanical Ventilators
Viral Load
Coinfection
Antiviral Agents
Immunoglobulins
Vaccination
Outpatients
Therapeutics
Animal Models

Keywords

  • acute respiratory tract infections
  • human metapneumovirus
  • human metapneumovirus infection
  • human metapneumovirus vaccine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Metapneumovirus Infections and Respiratory Complications. / Esposito, Susanna; Mastrolia, Maria Vincenza.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 37, No. 4, 01.08.2016, p. 512-521.

Research output: Contribution to journalArticle

Esposito, Susanna ; Mastrolia, Maria Vincenza. / Metapneumovirus Infections and Respiratory Complications. In: Seminars in Respiratory and Critical Care Medicine. 2016 ; Vol. 37, No. 4. pp. 512-521.
@article{17f703a11085482fa916a7246f99e789,
title = "Metapneumovirus Infections and Respiratory Complications",
abstract = "Acute respiratory tract infections (ARTIs) are the most common illnesses experienced by people of all ages worldwide. In 2001, a new respiratory pathogen called human metapneumovirus (hMPV) was identified in respiratory secretions. hMPV is an RNA virus of the Paramyxoviridae family, and it has been isolated on every continent and from individuals of all ages. hMPV causes 7 to 19{\%} of all cases of ARTIs in both hospitalized and outpatient children, and the rate of detection in adults is approximately 3{\%}. Symptoms of hMPV infection range from a mild cold to a severe disease requiring a ventilator and cardiovascular support. The main risk factors for severe disease upon hMPV infection are the presence of a high viral load, coinfection with other agents (especially human respiratory syncytial virus), being between 0 and 5 months old or older than 65 years, and immunodeficiency. Currently, available treatments for hMPV infections are only supportive, and antiviral drugs are employed in cases of severe disease as a last resort. Ribavirin and immunoglobulins have been used in some patients, but the real efficacy of these treatments is unclear. At present, the direction of research on therapy for hMPV infection is toward the development of new approaches, and a variety of vaccination strategies are being explored and tested in animal models. However, further studies are required to define the best treatment and prevention strategies.",
keywords = "acute respiratory tract infections, human metapneumovirus, human metapneumovirus infection, human metapneumovirus vaccine",
author = "Susanna Esposito and Mastrolia, {Maria Vincenza}",
year = "2016",
month = "8",
day = "1",
doi = "10.1055/s-0036-1584800",
language = "English",
volume = "37",
pages = "512--521",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Metapneumovirus Infections and Respiratory Complications

AU - Esposito, Susanna

AU - Mastrolia, Maria Vincenza

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Acute respiratory tract infections (ARTIs) are the most common illnesses experienced by people of all ages worldwide. In 2001, a new respiratory pathogen called human metapneumovirus (hMPV) was identified in respiratory secretions. hMPV is an RNA virus of the Paramyxoviridae family, and it has been isolated on every continent and from individuals of all ages. hMPV causes 7 to 19% of all cases of ARTIs in both hospitalized and outpatient children, and the rate of detection in adults is approximately 3%. Symptoms of hMPV infection range from a mild cold to a severe disease requiring a ventilator and cardiovascular support. The main risk factors for severe disease upon hMPV infection are the presence of a high viral load, coinfection with other agents (especially human respiratory syncytial virus), being between 0 and 5 months old or older than 65 years, and immunodeficiency. Currently, available treatments for hMPV infections are only supportive, and antiviral drugs are employed in cases of severe disease as a last resort. Ribavirin and immunoglobulins have been used in some patients, but the real efficacy of these treatments is unclear. At present, the direction of research on therapy for hMPV infection is toward the development of new approaches, and a variety of vaccination strategies are being explored and tested in animal models. However, further studies are required to define the best treatment and prevention strategies.

AB - Acute respiratory tract infections (ARTIs) are the most common illnesses experienced by people of all ages worldwide. In 2001, a new respiratory pathogen called human metapneumovirus (hMPV) was identified in respiratory secretions. hMPV is an RNA virus of the Paramyxoviridae family, and it has been isolated on every continent and from individuals of all ages. hMPV causes 7 to 19% of all cases of ARTIs in both hospitalized and outpatient children, and the rate of detection in adults is approximately 3%. Symptoms of hMPV infection range from a mild cold to a severe disease requiring a ventilator and cardiovascular support. The main risk factors for severe disease upon hMPV infection are the presence of a high viral load, coinfection with other agents (especially human respiratory syncytial virus), being between 0 and 5 months old or older than 65 years, and immunodeficiency. Currently, available treatments for hMPV infections are only supportive, and antiviral drugs are employed in cases of severe disease as a last resort. Ribavirin and immunoglobulins have been used in some patients, but the real efficacy of these treatments is unclear. At present, the direction of research on therapy for hMPV infection is toward the development of new approaches, and a variety of vaccination strategies are being explored and tested in animal models. However, further studies are required to define the best treatment and prevention strategies.

KW - acute respiratory tract infections

KW - human metapneumovirus

KW - human metapneumovirus infection

KW - human metapneumovirus vaccine

UR - http://www.scopus.com/inward/record.url?scp=84982690290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982690290&partnerID=8YFLogxK

U2 - 10.1055/s-0036-1584800

DO - 10.1055/s-0036-1584800

M3 - Article

AN - SCOPUS:84982690290

VL - 37

SP - 512

EP - 521

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 4

ER -